Director Wei-Wu He's Group Increases Stake to 45.4% via Convertible Notes, Bolstering Control

summarizeSummary

Dr. Wei-Wu He and his affiliated investment group have increased their beneficial ownership in CASI Pharmaceuticals to 45.4% through convertible notes, significantly strengthening their control.

check_boxKey Events

• Increased Beneficial Ownership

  Dr. Wei-Wu He and his affiliated entities now beneficially own 13,965,535 ordinary shares, representing 45.4% of the company's outstanding shares.

• Convertible Note Impact

  The increased stake includes 10,000,000 shares issuable upon conversion of two $5 million convertible notes, dated December 27, 2025, and January 9, 2026, respectively. The conversion price for these notes is between $1.00 and $2.00 per share, with an assumed conversion price of $1.00.

• Strengthened Control

  This significant accumulation of shares by a director who previously proposed a take-private transaction enhances his influence over the company's future direction and potential corporate actions.

• Follows Recent Financing

  This filing formalizes the beneficial ownership impact of the $5 million second tranche convertible note financing, which was previously announced on January 13, 2026, and consolidates the ownership from both recent notes.

auto_awesomeAnalysis

This Schedule 13D/A filing reveals a significant increase in beneficial ownership by Dr. Wei-Wu He and his affiliated entities, now holding 45.4% of CASI Pharmaceuticals. This substantial stake, primarily accumulated through the conversion rights of two $5 million convertible notes (dated December 27, 2025, and January 9, 2026), solidifies Dr. He's control over the company. This development is particularly critical given Dr. He's previous non-binding proposal to acquire all public shares, suggesting a potential path towards a take-private transaction. While the capital infusion from the notes provides necessary funding, the increased concentration of ownership could impact minority shareholder interests and future corporate governance decisions.